Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

ENTA has been the subject of a number of other research reports. Zacks Investment Research cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, June 21st. JMP Securities raised shares of Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 price objective for the company in a research report on Tuesday, July 11th. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $38.00 price objective (up previously from $32.00) on shares of Enanta Pharmaceuticals in a research report on Wednesday. ValuEngine raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Robert W. Baird increased their price objective on shares of Enanta Pharmaceuticals from $27.00 to $36.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 8th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $36.00.

Shares of Enanta Pharmaceuticals (NASDAQ ENTA) opened at 39.16 on Friday. Enanta Pharmaceuticals has a one year low of $21.00 and a one year high of $41.20. The stock’s market cap is $747.17 million. The company has a 50 day moving average price of $37.42 and a 200-day moving average price of $32.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.05. The firm had revenue of $7.51 million during the quarter, compared to analysts’ expectations of $8.08 million. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The firm’s quarterly revenue was down 46.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.06) EPS. Equities analysts predict that Enanta Pharmaceuticals will post $0.90 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Enanta Pharmaceuticals, Inc. (ENTA) Lifted to Buy at BidaskClub” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/13/enanta-pharmaceuticals-inc-enta-lifted-to-buy-at-bidaskclub.html.

Several institutional investors have recently bought and sold shares of ENTA. Mason Street Advisors LLC boosted its position in Enanta Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock worth $100,000 after buying an additional 212 shares during the last quarter. GAM Holding AG acquired a new position in shares of Enanta Pharmaceuticals during the second quarter valued at approximately $108,000. Municipal Employees Retirement System of Michigan boosted its position in shares of Enanta Pharmaceuticals by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 110 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Enanta Pharmaceuticals by 5.8% in the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 237 shares in the last quarter. Finally, BNP Paribas Arbitrage SA boosted its position in shares of Enanta Pharmaceuticals by 62.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 1,702 shares in the last quarter. 65.95% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.